



# ZONE STUDY

**A Phase 2a study of effect of ZT-01 On Nocturnal hypoglycemia Events in type 1 diabetes**

---

The study drug ZT-01 is designed to inhibit somatostatin, a hormone that inhibits the glucagon response to hypoglycemia. ZT-01 may be able to restore glucagon production to prevent hypoglycemia, which could improve both health and quality of life in people with T1DM.

---

This study has been approved by the University of Calgary Conjoint Health Research Ethics Board (REB25-1093).

**You may qualify if:**

**You are aged 18-75**

**You have had type 1 diabetes for more than 5 years**

**You have a recent history suggestive of hypoglycemia events at night**

## **CONTACT**

Jenny Schulz

jennifer.schulz@ucalgary.ca  
403-955-8119